GLOW Blend
Fixed-ratio skin & tissue-repair blend · GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg
GLOW packs 50 mg of the copper peptide GHK-Cu with 10 mg each of BPC-157 and TB-500 into one vial, a fixed 5 : 1 : 1. People run it for firmer skin, cleaner-healing scars and connective-tissue repair. One daily draw delivers all three.
At a glance
- Dose
- ≈ 1.2–3.5 mg of blend a day, most run ≈ 2.3 mg
- How often
- Once daily
- How
- A small injection under the skin, all three in one syringe
- When
- Evening, to ride your overnight repair window
- Cycle
- 4-week blocks with 2–4 weeks off (8–12 weeks for skin remodeling)
The 30-second versionEverything on this page, fast
Skin & scar remodeling · Collagen support · Tissue repair · Three peptides, one draw
Three repair peptides in one syringe. GLOW combines GHK-Cu's collagen and matrix remodeling, BPC-157's blood-supply-building repair and TB-500's repair-cell migration in a single 70 mg vial. It is the blend people reach for when skin, scars and connective tissue are the goal.
The basics
- A pre-mixed powder: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 (a 5 : 1 : 1 ratio). One vial, one draw, all three every time.
- The skin member of the blend family, since GHK-Cu leads by weight. Wolverine is the same pair without the copper peptide, and KLOW adds KPV on top.
Why people use it
- Firmer, smoother-looking skin. GHK-Cu switches on collagen, elastin and the skin's matrix in skin cells.
- Scars and wounds heal with better blood supply. BPC-157 grows new vessels into the repair zone while TB-500 pulls repair cells in.
- One shot instead of three. The whole recovery-and-remodeling trio in a single daily draw.
- Works body-wide. TB-500 and BPC-157 circulate, so the signal reaches tissue far from the injection.
Stacks well with
- KPV when inflammation or reactive skin is in the picture. Adding it turns GLOW into KLOW, co-injected or as the four-peptide vial.
- Wolverine Blend or separate BPC-157 + TB-500 vials when the goal is an injury rather than skin. The copper-free pair lets you push those two harder without raising the GHK-Cu load.
Good to know
- The ratio sets the ceiling. At 10 units BPC-157 and TB-500 sit in their own standard ranges while GHK-Cu is already in its high band, and by 12 units it reaches the 2 mg a day its page tops out at. A high-dose injury run wants separate vials.
- A faint blue tint is normal. That is the copper in GHK-Cu. A 10-unit dose carries about 0.26 mg of copper, and injected copper skips the gut's usual regulation, so don't add copper supplements on top.
- Banned in tested sport. BPC-157 and TB-500 are both on the WADA list.
- Once mixed, refrigerate and finish it within about 4 weeks. One vial at 10 units is 30 doses.
What it does
The blend people reach for when skin, scars and connective tissue are the goal and one vial beats three.
- Firmer, smoother-looking skinIn thigh skin biopsies, collagen production rose in 70% of women using GHK-Cu cream, versus 50% with vitamin C cream.
- Scars that heal with better blood supplyBPC-157 gel raised VEGF, a vessel-growth signal, in rat burn wounds, which closed about 80% versus 60% on plain gel.
- Faster wound closure in a human trialIn a randomized diabetic foot-ulcer trial, GHK-Cu gel closed a median 98.5% of ulcer area, versus 60.8% on plain gel.
- A repair signal for the whole bodyGiven into the belly cavity or on skin, Thymosin β4 raised new-skin cover on rat wounds 42% by day 4.
- More collagen built in healing woundsInjected into rat wound chambers, GHK-Cu raised collagen synthesis twice as much as other proteins and turned up collagen genes.
Sources:PMID 26236730PMID 25995620PMID 17147644PMID 10469335PMID 8227353
How it works
Three peptides, one draw. GLOW is one freeze-dried powder, so every draw carries GHK-Cu, BPC-157 and TB-500 in fixed proportions.
GHK-Cu remodels the matrix. In cultured skin fibroblasts, the cells that build connective tissue, it switches on collagen, elastin and the supporting matrix. Its copper feeds lysyl oxidase, which cross-links new collagen.
BPC-157 builds blood supply, TB-500 brings the cells. BPC-157 switches on angiogenesis, new vessels feeding a healing site, and speeds fibroblast migration. TB-500, synthetic Thymosin β4, controls actin, the protein cells move with, so repair cells arrive faster.
Copper in the vial. Copper on GHK stayed inert in one lab study and made hydroxyl radical with vitamin C in another. Radicals oxidize methionine. TB-500 has one, BPC-157 none.
Sources:PubChem CID 9941957PubChem CID 16132341PubChem CID 71587328PMID 21780203PMID 17577900PMID 14661084PMID 8227353PMID 26236730PMID 27847966PMID 21030672PMID 10469335PMID 25313062PMID 34992578
How to dose it
One daily injection under the skin, measured as total blend on a U-100 syringe. Pick the units; the ratio sets each peptide's dose.
Dose tiersMost people run ~2.3 mg, which takes 10 units at the standard mix. Once a day.
- Low / first week, 5 units (≈ 1.2 mg):
- ≈ 833 mcg GHK-Cu + 167 mcg BPC-157 + 167 mcg TB-500 a day, for the first week or light skin maintenance.
- Standard, 10 units (≈ 2.3 mg):
- ≈ 1.67 mg GHK-Cu + 333 mcg BPC-157 + 333 mcg TB-500 daily. BPC-157 sits mid-range, TB-500 (≈ 2.3 mg/week) in its maintenance band, and GHK-Cu in its high band.
- High / ceiling, 15 units (≈ 3.5 mg):
- ≈ 2.5 mg GHK-Cu + 500 mcg BPC-157 + 500 mcg TB-500 daily, the top end. GHK-Cu is past its 2 mg/day top; that copper load sets the ceiling.
How to injectOne injection into body fat, once a day. Rotate sites; keep a consistent evening slot.
- Injection site:
- Belly (two inches from the navel), love handles or outer thigh. Rotate daily; people report site irritation most with copper solutions. Near a scar is optional.
- Measuring the dose:
- U-100 syringe, 70 mg + 3 mL. 5, 10 and 15 units hold about 1.2, 2.3 and 3.5 mg of blend.
- Time of day:
- Evening. A consistent daily time matters more than the hour; morning is fine if evening doesn't fit.
- Food window:
- Meals don't matter; none of the three competes with food for absorption.
Cycle and breaksOne vial at 10 units is a 4-week block; skin runs go 8–12 weeks.
- Standard block:
- 4 weeks at 10 units a day, then 2–4 weeks off. One 70 mg vial covers it (30 doses in the vial, 28 in the block).
- Skin-remodeling run:
- 8–12 weeks of daily use (two to three vials) for scar, texture and post-procedure goals, then a 4-week break. Many taper to 5 units for the back half.
- Washout:
- 2–4 weeks off after a 4-week block, 4 weeks after a long run. Judge progress during the break, with photographs rather than memory.
- Loading, if an injury is the reason:
- GLOW isn't built for TB-500 loading (2–2.5 mg twice weekly, 4–5 mg/week). For an injury, some add one separate 2–2.5 mg TB-500 dose a week for the first 4–6 weeks.
Mixing the vial70 mg + 3 mL bacteriostatic water is the standard mix; the calculator splits any draw.
- Standard mix, 3 mL:
- 70 mg + 3 mL = 23,333 mcg/mL. Each unit holds ~167 mcg GHK-Cu + 33 mcg BPC-157 + 33 mcg TB-500; 10 units hold about 2,333 mcg of blend.
- Compact mix, 2 mL:
- 70 mg + 2 mL = 35,000 mcg/mL, so each unit holds ~350 mcg and 2.33 mg takes about 6.5 units. Don't switch water mid-vial without redoing the math.
- Read the split:
- The syringe measures total blend; compare the calculator's per-component readout against each peptide's own page. The split assumes 50/10/10; check your label.
- Copper arithmetic:
- GHK-Cu is 15.8 % copper: a 70 mg vial holds ≈ 7.9 mg and a 10-unit dose ≈ 0.26 mg, injected past the gut's regulation.
Sources:PMID 8227353PMID 26236730PMID 27847966PMID 36588717PMID 10469335PMID 34346165PubChem CID 71587328
Best time to take it
Implied best time
Evening
Most people inject GLOW in the evening, so all three repair signals line up with overnight recovery.
- Overnight is when the body rebuilds most. Deep sleep brings the natural growth-hormone pulse, peak tissue regeneration and the least load on healing tissue.
- None of the three keeps a clock. BPC-157 clears within minutes, TB-500 within about two hours; what counts is the signal each leaves behind.
- One daily draw, so no split schedule. Keep a consistent evening slot. Morning works if evening doesn't fit; the habit matters more than the hour.
Sources:PMID 36588717PMID 34346165
What to stack it with
GLOW already stacks three repair signals. Useful additions come from another angle, calming inflammation, a growth-hormone backdrop, or separate vials when one peptide goes higher.
GLOW + KPVThe most common addition, an anti-inflammatory brake on top of the three repair signals.
- Why it works:
- KPV turns down NF-κB, the master inflammatory switch, so repair happens in calmer tissue, a lever the blend lacks. Pre-mixed, it is KLOW (80 mg: GLOW plus 10 mg KPV).
- The protocol:
- GLOW 10 units plus KPV 300–500 mcg, both daily, co-drawn or at a second site. Or a KLOW vial: 10 units daily gives the same split plus 333 mcg KPV.
- Outcome:
- People run it on reactive or inflamed skin, post-procedure redness, and any repair goal where inflammation is part of the problem.
GLOW + separate BPC-157 / TB-500 top-upsFor an injury that needs more BPC-157 or TB-500 than 10 units of GLOW gives.
- Why it works:
- GHK-Cu sets the blend's ceiling, not BPC-157 or TB-500. Their own vials take BPC-157 above its 333 mcg and TB-500 to 4–5 mg/week loading without pushing GHK-Cu past 2 mg/day.
- The protocol:
- GLOW 10 units daily plus BPC-157 250 mcg daily, the top-up ceiling, and/or one 2–2.5 mg TB-500 dose a week for the first 4–6 weeks. Co-draw with GLOW; rotate sites.
- Outcome:
- Reached for when a tendon, ligament or post-surgical recovery is the real target and skin is the bonus. Many run Wolverine for the injury instead and keep GLOW for skin.
GLOW + CJC-1295 / IpamorelinA growth-hormone backdrop under the local repair signals, a lever the blend doesn't have.
- Why it works:
- CJC-1295 and Ipamorelin raise the body's overnight growth-hormone pulse, which drives whole-body protein synthesis and skin thickness. A different axis from GLOW's local repair, so it adds instead of repeating.
- The protocol:
- GLOW 10 units in the evening. The GH pair: 100 mcg CJC-1295 (no DAC) + 200–300 mcg Ipamorelin at bedtime, fasted, or the pre-mixed blend. GLOW needs no fasted window.
- Outcome:
- Reached for on body-composition-plus-skin goals and slow post-injury recoveries that want a GH backdrop under the repair trio.
Support nutrients
Supply the collagen the peptides build with, feed the nitric-oxide pathway, and go easy on copper, since GLOW already delivers it.
Collagen building blocksAll three peptides signal for new tissue; this supplies the raw material.
- Hydrolyzed collagen:
- 10–15 g hydrolyzed collagen, 30–60 minutes before activity or with the evening injection.
- Glycine and proline:
- The bulk of the collagen sequence. Protein at 1.6–2.0 g/kg/day keeps the pool full; 3–5 g of glycine is a common addition during a remodeling run.
Go easy on copperA 10-unit dose already delivers ≈ 0.26 mg of copper by injection, past the gut's regulation.
- No added copper:
- Skip copper supplements while running GLOW; the blend itself feeds lysyl oxidase, the collagen cross-linking enzyme. The 1–2 mg copper BPC-157 and TB-500 users add is already covered.
- Zinc 15–30 mg, keep it moderate:
- Zinc drives the enzymes that clear old matrix. It competes with copper for absorption, and ≈ 60 mg/day for weeks depletes copper, so keep it at 15–30 mg with food.
Feed the nitric-oxide pathwayBPC-157 signals through nitric oxide; new vessels need it to dilate and feed the repair.
- L-arginine or L-citrulline:
- L-arginine 3–6 g/day or L-citrulline 3 g/day. Arginine is the raw material for the nitric-oxide enzyme BPC-157 switches on. Morning or pre-workout; skip it if blood pressure runs low.
Dose calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
10 units
Draw this many units on a U-100 syringe
Each unit holds 233.3 mcg
This dose contains
- GHK-Cu1.67 mg
- BPC-157333 mcg
- TB-500333 mcg
Fixed ratio. Every draw carries all of the vial's peptides in the same proportions; only the total changes.
- Volume per dose
- 0.1 mL
- Doses per vial
- 30
- Concentration
- 23.33 mg/mL
One vial lasts
- Daily
- 30 days
- Every other day
- 60 days
- 5×/week
- 42 days
Research use only. Not for human consumption. Outputs are reference values based on research literature. Verify all measurements independently.
Side effects and what to watch
What people notice. Injection-site irritation, the common complaint with copper blends. Rotate sites.
Worth knowing. BPC-157's animal studies found no lethal dose. In 28-day studies, clotting time shifted in rats and dogs, and dogs' creatinine dipped and recovered. Human intravenous Thymosin β4 trials reached 1,260 mg with no dose-limiting toxicity.
A human report. A woman on a BPC-157 and TB-500 product had skin and gum darkening that returned when she restarted and did not recur after she quit.
The copper. A 10-unit dose injects about 0.26 mg of copper past the gut's controls, so the GHK-Cu share sets the dose ceiling.
How people handle it. If one peptide reacts, lower the whole dose or go to separate vials; the ratio is fixed.
Skip it or take care if. You have an active or recent cancer, since TB-500 promotes vessel growth and cell migration.
Sources:PMID 32334036PMID 34346165PMID 20536472PMID 34992578FDA briefing document (BPC-157), PCAC July 2026
Common questions
What is in a GLOW vial?
70 mg of powder: 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, freeze-dried together at 5 : 1 : 1. Other vial sizes exist, so check the label's ratio.
How is it dosed?
Most people run 10 units a day under the skin, about 2.3 mg of blend, in the evening. 5 units for a first week, 15 units is the top.
How much of each peptide is in 10 units?
At the standard mix (70 mg + 3 mL), 10 units hold about 2.33 mg of blend: ≈ 1.67 mg GHK-Cu, 333 mcg BPC-157 and 333 mcg TB-500.
GLOW, KLOW or Wolverine?
They nest. Wolverine is BPC-157 + TB-500, for injuries; GLOW adds 50 mg GHK-Cu, for skin and scars; KLOW adds 10 mg KPV on top, for inflamed skin.
Does the copper damage the BPC-157 in the vial?
One lab study found copper held by GHK inert under mild conditions. Another found it made hydroxyl radical with vitamin C. Radicals oxidize methionine easily. TB-500 has one. BPC-157 has none. Refrigerate and finish within about four weeks.
Do I need to cycle GLOW?
Most run 4 weeks at 10 units, one vial, then 2–4 weeks off. Skin-remodeling runs go 8–12 weeks, then a 4-week break.
Deep dive
Doses used in studies · Molecular identity · References
10From the researchDoses used in studies
The doses used in the studies behind each component, mostly rodent and per kilogram of body weight; GHK-Cu's human study used a topical cream.
| Dose | Route | Model | Outcome | Sources: |
|---|---|---|---|---|
| Any | Subcutaneous | No study of the three-peptide blend | No published study has tested GHK-Cu + BPC-157 + TB-500 together; the 50/10/10 vial ratio is a market convention, not a studied formulation | |
| Local intra-wound injection | Injected (local, intra-wound) | Rat, experimental wound chambers (GHK-Cu) | Locally injected GHK-Cu stimulated connective-tissue/collagen accumulation; local delivery, not systemic dosing | PMID 8227353 |
| Low-percentage facial cream (<1%) | Topical | Human, 12-week cosmetic study (GHK-Cu; industry-sponsored) | Reported improvements in skin firmness, clarity, and density vs comparators; low-tier evidence | AAD Annual Meeting 2002 (conference presentation) |
| 10 µg/kg | Intraperitoneal | Rat (ligament), BPC-157 | Ligament healing + biomechanics | PMID 20225319 |
| 20–500 µg/kg | IV & IM | Rat (PK), BPC-157 | Pharmacokinetics (n=6/group) | PMID 36588717 |
| Topical / IP | Topical / IP | Rat (dermal wound), TB-500 | +42% re-epithelialization (d4), +61% (d7) | PMID 10469335 |
| 0.05–25 µg/kg | Intravenous | Human (Phase I PK/safety, n=84), TB-500 | Dose-proportional PK; no dose-limiting toxicity | PMID 34346165 |
11ChemistryMolecular identity
- Composition
- GHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg = 70 mg per vialCross-source vendor agreement
- Ratio
- 5 : 1 : 1 by mass, 71.4 % GHK-Cu · 14.3 % BPC-157 · 14.3 % TB-500Calculated
- Structure / class
- Fixed-ratio, co-lyophilized blend of three research peptides in one vial, not a new molecule; each component keeps its own identity and pharmacologyCross-source vendor agreement
- GHK-Cu (50 mg)
- Gly-His-Lys · Cu(II) chelate · C14H23CuN6O4+ · 402.92 g/mol · CAS 89030-95-5PubChem CID 71587328
- BPC-157 (10 mg)
- GEPPPGKPADDAGLV (15 AA) · C62H98N16O22 · 1,419.5 g/mol · CAS 137525-51-0PubChem CID 9941957
- TB-500 (10 mg)
- Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 AA) · C212H350N56O78S · ~4,963 g/mol · CAS 77591-33-4UniProt P62328; PubChem CID 16132341
- Copper per vial
- ≈ 7.9 mg elemental copper; GHK-Cu is 15.8 % copper by mass; ≈ 0.26 mg per 10-unit dose (adult oral RDA 0.9 mg/day; oral UL 10 mg/day, not an injected-copper limit)Calculated from PubChem masses
- Half-life (per component)
- No single clock. BPC-157 clears within minutes (rat IV), TB-500 within roughly half an hour to two hours (human IV), GHK-Cu not established; the blend inherits three separate curves, not onePMID 36588717 · PMID 34346165 · PMID 20536472
- Regulatory status
- Not an approved drug in any form; no trial has tested the three-peptide combination; BPC-157 and TB-500 are prohibited in sport (WADA S0 / S2.3)FDA / WADA Prohibited List
12Primary sourcesReferences
- PubChem CID 71587328PubChem CID 71587328 (Prezatide copper / GHK-Cu complex; C14H23CuN6O4+, MW 402.92; Cu(II) chelate)
- PubChem CID 9941957PubChem CID 9941957 (BPC-157; C62H98N16O22; no sulfur, so no methionine or cysteine)
- PubChem CID 16132341PubChem CID 16132341 (Thymosin β4 / TB-500; one methionine, no cysteine)
- PMID 21780203Hureau et al., structures and redox properties of the Cu(II) complexes of GHK and DAHK (inert under moderate redox potentials; copper swaps fast between GHK molecules), Chem Eur J 2011
- PMID 17577900Guilloreau et al., ChemBioChem 2007 (with ascorbate, Cu-GHK made more hydroxyl radical than Cu-amyloid-beta or Cu-DAHK)
- PMID 14661084Stadtman & Levine, Amino Acids 2003 (free-radical oxidation of amino acid residues; surface methionine and cysteine are especially sensitive)
- PMID 8227353Maquart et al., J Clin Invest 1993 (in-vivo: locally injected GHK-Cu stimulates connective-tissue/collagen accumulation in rat wound chambers)
- PMID 26236730Pickart, Vasquez-Soltero & Margolina, Biomed Res Int 2015 (regenerative & protective actions of GHK in skin, review)
- AAD Annual Meeting 2002 (conference presentation)Leyden, Stephens, Finkey, Appa & Barkovic. Facial & periorbital GHK-Cu cream cosmetic studies (industry-sponsored; no PMID located)
- PMID 27847966J. Mol. Med. 2017 (BPC-157, VEGFR2/angiogenesis)
- PMID 21030672J. Appl. Physiol. 2011 (BPC-157, fibroblast FAK/paxillin migration)
- PMID 20225319J. Orthop. Res. 2010 (BPC-157, rat ligament healing)
- PMID 36588717Front. Pharmacol. 2022 (BPC-157, rat/dog pharmacokinetics)
- PMID 32334036Regul. Toxicol. Pharmacol. 2020 (BPC-157, formal animal safety/toxicology)
- PMID 10469335J Invest Dermatol 1999 (Tβ4 wound healing, rat)
- PMID 25313062PNAS 2014 (structural basis, Tβ4–actin)
- PMID 34992578Front. Endocrinol. 2021 (Tβ4 function & application review)
- PMID 34346165J Cell Mol Med 2021 (Phase I rhTβ4, IV PK/safety)
- PMID 20536472Phase I synthetic Tβ4, IV PK/safety
- PMID 36613994RGN-259 Phase III neurotrophic keratopathy (Tβ4 eye drops)
- PMID 9587142Rucker et al. 1998 (copper and lysyl oxidase cross-linking)
- PMC5793244Zinc in wound healing (review)
- NIH ODSNIH Office of Dietary Supplements, Copper fact sheet for health professionals (adult RDA 900 mcg/day; UL 10 mg/day; high-dose zinc depletes copper)
- WADAWADA Prohibited List (BPC-157 S0; Thymosin β4 S2.3; prohibited at all times)
- PMID 25995620Huang et al., Drug Des Devel Ther 2015 (topical BPC-157 on alkali-burn wounds in rats)
- PMID 17147644Mulder et al., Wound Repair Regen 1994 (randomized, evaluator-blinded, placebo-controlled GHK-Cu gel trial in diabetic foot ulcers)
- FDA briefing document (BPC-157), PCAC July 2026FDA briefing document on BPC-157, Pharmacy Compounding Advisory Committee, July 23-24, 2026
Reviewed by Ki Researcher Team · Research use only · Not medical advice · Updated 2026-10-19